- Home
- APLT vs CLSD Comparison
APLT vs CLSD Comparison
Compare APLT & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- CLSD
- Stock Information
- Founded
- APLT 2016
- CLSD 2011
- Country
- APLT United States
- CLSD United States
- Employees
- APLT N/A
- CLSD N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- CLSD Health Care
- Exchange
- APLT Nasdaq
- CLSD Nasdaq
- Market Cap
- APLT 80.3M
- CLSD 81.2M
- IPO Year
- APLT 2019
- CLSD 2016
- Fundamental
- Price
- APLT $0.53
- CLSD $0.95
- Analyst Decision
- APLT Buy
- CLSD Strong Buy
- Analyst Count
- APLT 7
- CLSD 6
- Target Price
- APLT $6.10
- CLSD $5.33
- AVG Volume (30 Days)
- APLT 3.0M
- CLSD 214.9K
- Earning Date
- APLT 03-05-2025
- CLSD 03-11-2025
- Dividend Yield
- APLT N/A
- CLSD N/A
- EPS Growth
- APLT N/A
- CLSD N/A
- EPS
- APLT N/A
- CLSD N/A
- Revenue
- APLT N/A
- CLSD $7,703,000.00
- Revenue This Year
- APLT N/A
- CLSD N/A
- Revenue Next Year
- APLT $2,622.90
- CLSD $91.87
- P/E Ratio
- APLT N/A
- CLSD N/A
- Revenue Growth
- APLT N/A
- CLSD 248.39
- 52 Week Low
- APLT $0.53
- CLSD $0.80
- 52 Week High
- APLT $10.62
- CLSD $2.12
- Technical
- Relative Strength Index (RSI)
- APLT 29.75
- CLSD 43.06
- Support Level
- APLT $0.54
- CLSD $1.00
- Resistance Level
- APLT $0.70
- CLSD $1.09
- Average True Range (ATR)
- APLT 0.06
- CLSD 0.07
- MACD
- APLT 0.06
- CLSD -0.01
- Stochastic Oscillator
- APLT 0.00
- CLSD 16.30
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.